Abstract
BioLineRx's deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma. It remains unclear whether the university's TLR4 inhibitors will work in other tissues affected by the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have